More on Seattle Genetics' Q4: Though results beat estimates, the company is declining to provide...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

More on Seattle Genetics' Q4: Though results beat estimates, the company is declining to provide 2012 guidance for sales of its Adcetris lymphoma drug. Adcetris accounted for over 2/3 of Seattle Genetics' Q4 revenue. SGEN -7.3% AH. (PR)